journal article·2018-11-05Open access

Phage display selection of fully human antibody fragments to inhibit growth-promoting effects of glycine-extended gastrin 17 on human colorectal cancer cells

Shirin Khajeh, Mohammad Reza Tohidkia, Ayuob Aghanejad, Tayebeh Mehdipour, Farzaneh Fathi, Yadollah Omidi

Abstract

Glycine-extended gastrin 17 (G17-Gly), a dominant processing intermediate of gastrin gene, has been implicated in the development or maintenance of colorectal cancers (CRCs). Hence, neutralizing G17-Gly activity by antibody entities can provide a potential therapeutic strategy in the patients with CRCs. To this end, we isolated fully human antibody fragments from a phage antibody library through biopanning against different epitopes of G17-Gly in order to obtain the highest possible antibody diversity. ELISA screening and sequence analysis identified 2 scFvs and 4 VL antibody fragments. Kinetic analysis of the antibody fragments by SPR revealed KD values to be in the nanomolar range (87.9–334 nM). The selected anti-G17-Gly antibody fragments were analyzed for growth inhibition and apoptotic assays in a CRC cell line, HCT-116, which is well-characterized for expressing gastrin intermediate species but not amidated gastrin. The antibody fragments exhibited significant inhibition of HCT-116 cells proliferation ranging from 36.5 to 73% of controls. Further, Annexin V/PI staining indicated that apoptosis rates of scFv H8 and VL G8 treated cells were 45.8 and 63%, respectively. Based on these results, we for the first time, demonstrated the isolation of anti-G17-Gly human scFv and VL antibodies with potential therapeutic applications in G17-Gly-responsive tumors.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · Glycosylation and Glycoproteins Research · RNA and protein synthesis mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biology, Faculty of Science, Islamic Azad University, Urmia Branch, Urmia, Iran;

Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran

Funding

Research Center for Pharmaceutical Nanotechnology

References (25)

Show source-provided references
1. Xiang B · Discov Med · 2013 · 15 · 301
2. 10.1038/onc.2014.25510.1038/onc.2014.255 ↗
3. 10.2174/09298660978983926910.2174/092986609789839269 ↗
4. 10.1016/S0016-5085(98)70193-310.1016/S0016-5085(98)70193-3 ↗
5. 10.1002/ijc.148310.1002/ijc.1483 ↗
6. 10.1172/JCI491010.1172/JCI4910 ↗
7. 10.1016/j.canlet.2006.11.01210.1016/j.canlet.2006.11.012 ↗
8. 10.1016/S1380-2933(98)00007-410.1016/S1380-2933(98)00007-4 ↗
9. 10.1093/protein/gzv02410.1093/protein/gzv024 ↗
10. 10.1016/0016-5085(93)90279-L10.1016/0016-5085(93)90279-L ↗
11. 10.1016/j.peptides.2005.02.00110.1016/j.peptides.2005.02.001 ↗
12. 10.1016/j.toxicon.2012.08.01410.1016/j.toxicon.2012.08.014 ↗
13. 10.1002/jmr.73510.1002/jmr.735 ↗
14. 10.1007/s40259-012-0007-010.1007/s40259-012-0007-0 ↗
15. Tohidkia MR · SLAS Discov · 2017 · 22 · 102610.1177/2472555217701059 ↗
16. 10.1016/0022-2836(91)90498-U10.1016/0022-2836(91)90498-U ↗
17. 10.1038/nprot.2011.44810.1038/nprot.2011.448 ↗
18. 10.1080/21691401.2017.135531110.1080/21691401.2017.1355311 ↗
19. 10.1016/j.canlet.2005.06.02510.1016/j.canlet.2005.06.025 ↗
20. 10.1007/s00280-014-2520-y10.1007/s00280-014-2520-y ↗
21. 10.1097/MPA.0b013e31822ade7e10.1097/MPA.0b013e31822ade7e ↗
22. 10.1097/CEJ.000000000000000810.1097/CEJ.0000000000000008 ↗
23. 10.1016/j.regpep.2005.08.00210.1016/j.regpep.2005.08.002 ↗
24. 10.1002/ijc.2339510.1002/ijc.23395 ↗
25. Singh P · Am J Physiol · 1994 · 266 · G459